Hepatitis B is the only major bloodborne pathogen that can be prevented with a vaccine. While HIV and hepatitis C are also transmitted through blood and body fluids, neither has an approved vaccine. The hepatitis B vaccine has been available since the 1980s and remains one of the most effective tools for preventing a serious, potentially chronic infection.
Why Hepatitis B Is the One With a Vaccine
The three most common bloodborne pathogens are hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV. Of these three, only HBV has a characteristic that makes vaccine development straightforward: its surface protein is stable enough for the immune system to recognize and build lasting defenses against it.
The hepatitis B vaccine works by training your immune system to produce antibodies that target proteins on the virus’s outer shell. These antibodies block the virus from entering liver cells in two ways: they prevent the virus from latching onto the cell surface, and they block it from binding to a specific receptor that hepatitis B needs to slip inside. Once your antibody levels reach a protective threshold (generally above 10 mIU/mL on a blood test), your body can neutralize the virus before it establishes an infection.
Hepatitis C, by contrast, is extraordinarily difficult to vaccinate against. The virus has 7 known genotypes and more than 80 subtypes, making it even more genetically diverse than HIV. A successful vaccine would need to trigger immune responses broad enough to cover that massive range of viral variants. A few candidates have reached early-stage human trials, but none has come close to approval. HIV vaccine efforts face similar barriers of rapid mutation and immune evasion, and no approved vaccine exists despite decades of research.
How the Vaccine Is Given
The standard hepatitis B vaccination schedule for healthy adults involves three doses given at 0, 1, and 6 months. A newer two-dose option is also available, with doses spaced one month apart. Both schedules produce strong immune responses in the vast majority of people with healthy immune systems.
After completing the series, a blood test can confirm whether you’ve developed enough antibodies. An antibody level above 10 to 12 mIU/mL is considered protective. Levels below 5 mIU/mL mean you didn’t respond to the vaccine and may need to repeat the series. Values in between are considered indeterminate and typically warrant retesting.
People with weakened immune systems, such as those living with HIV, may have a harder time building a strong response. In clinical trials, higher-dose formulations have improved response rates in this group, with 72% achieving protective antibody levels compared to 51% on the standard dose.
How Long Protection Lasts
For most healthy people, the hepatitis B vaccine provides long-term protection against both acute and chronic infection. The CDC states that most healthy individuals do not need a booster dose after completing the initial series. Your immune system retains memory cells that can rapidly produce antibodies if you’re ever exposed, even years later when measurable antibody levels may have declined.
There are exceptions. People on dialysis, for instance, are typically monitored and revaccinated when their antibody levels drop below the protective threshold. But for the general population, the original series is considered sufficient for life.
Who Should Get Vaccinated
As of December 2024, the CDC recommends universal hepatitis B vaccination for all adults aged 19 through 59. Adults 60 and older with risk factors (such as healthcare work, sexual exposure, or injection drug use) are also recommended to receive it, and those without known risk factors can still choose to be vaccinated.
All infants in the United States receive the hepatitis B vaccine as part of the routine childhood immunization schedule. If you were born in the U.S. after 1991, you likely received the series as a baby. If you’re unsure, a simple blood test can check whether you have protective antibody levels.
Workplace Requirements for At-Risk Employees
Federal workplace safety law specifically addresses hepatitis B vaccination. Under OSHA’s Bloodborne Pathogens Standard, employers must offer the hepatitis B vaccine free of charge to all employees who have occupational exposure to blood or other potentially infectious materials. This includes healthcare workers, lab technicians, first responders, janitorial staff in medical settings, and others whose jobs put them in contact with blood.
The vaccine must be offered within 10 working days of an employee’s initial assignment to a position with occupational exposure, after required training has been completed. Employees can decline the vaccine, but the employer’s obligation to offer it is absolute. If an unvaccinated employee later has a needlestick or other exposure incident, the employer must provide post-exposure evaluation and follow-up.
What Happens After a Blood Exposure
If you’re already vaccinated and have a confirmed protective antibody level, a needlestick or splash exposure to hepatitis B-positive blood generally requires no additional treatment. Your existing immunity handles it.
For unvaccinated individuals or those who never responded to the vaccine, the situation is more urgent. Post-exposure treatment typically involves hepatitis B immune globulin, a concentrated dose of antibodies that provides immediate, temporary protection. This is usually given alongside the first dose of the vaccine series to provide both short-term and long-term defense. The same approach is used to prevent mother-to-child transmission when a baby is born to a hepatitis B-positive mother.
No equivalent post-exposure vaccine option exists for hepatitis C or HIV. Those exposures are managed with antiviral medications started as quickly as possible after the incident, which underscores why hepatitis B’s vaccine-preventable status is such a significant advantage in occupational safety.